Drugs / TALL-104
last change May 2013 re-read 2 minutes ago

TALL-104

Developed for
chronic myeloid leukemia
Investigated by
Abiogen Pharma · M.D. Anderson Cancer Center

Trials 1 · a red edge is where a trial was stopped

200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00415909 Dec 2006 → May 2013 chronic myeloid leukemia M.D. Anderson Cancer Center Terminated No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as TALL-104 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00415909
Route Intravenous “TALL-104 cells will be given intravenously over 1 hour” NCT00415909